S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

$39.62
-0.53 (-1.32%)
(As of 04/12/2024 ET)
Today's Range
$38.95
$40.18
50-Day Range
$39.62
$56.02
52-Week Range
$35.62
$67.66
Volume
392,144 shs
Average Volume
344,611 shs
Market Capitalization
$1.91 billion
P/E Ratio
15.36
Dividend Yield
N/A
Price Target
$66.00

Amphastar Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
66.6% Upside
$66.00 Price Target
Short Interest
Bearish
10.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
0.78mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$660,860 Sold Last Quarter
Proj. Earnings Growth
20.18%
From $3.42 to $4.11 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

37th out of 925 stocks

Pharmaceutical Preparations Industry

15th out of 422 stocks

AMPH stock logo

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock Price History

AMPH Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
AMPH Apr 2024 65.000 call
AMPH Apr 2024 60.000 put
LLY Mar 2024 980.000 call
Q4 2023 Amphastar Pharmaceuticals Inc Earnings Call
Here's what Wall Street expects from Amphastar Pharmaceuticals's earnings
Amphastar Pharmaceuticals, Inc.
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/13/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMPH
Employees
1,761
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$66.00
High Stock Price Target
$71.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+66.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$137.54 million
Pretax Margin
26.59%

Debt

Sales & Book Value

Annual Sales
$644.40 million
Cash Flow
$4.31 per share
Book Value
$13.35 per share

Miscellaneous

Free Float
34,437,000
Market Cap
$1.91 billion
Optionable
Optionable
Beta
0.84
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

AMPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $60.00 to $71.00. On average, they anticipate the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 66.6% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2024?

Amphastar Pharmaceuticals' stock was trading at $61.85 on January 1st, 2024. Since then, AMPH shares have decreased by 35.9% and is now trading at $39.62.
View the best growth stocks for 2024 here
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings results on Wednesday, February, 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.84 by $0.03. The company earned $178.11 million during the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a trailing twelve-month return on equity of 26.95%.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bridge City Capital LLC (0.07%), Annex Advisory Services LLC (0.03%) and Juncture Wealth Strategies LLC (0.02%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi.
View institutional ownership trends
.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMPH) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners